Y-mAbs to Announce Second Quarter 2022 Financial and Operating Results on August 8, 2022
August 02, 2022 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter that ended...
Y-mAbs’ Announces Clearance of IND for GD2-SADA
July 12, 2022 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, July 12, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Announces FDA Acceptance of Biologics License Application for OMBLASTYS® (omburtamab) for the Treatment of Neuroblastoma for Priority Review
May 31, 2022 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, May 31, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Announces Naxitamab Chemoimmunotherapy Investigational Trial for High-Risk Neuroblastoma Meets Primary Endpoint
May 26, 2022 16:01 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Announces First Quarter Financial Results and Recent Corporate Developments
May 09, 2022 16:01 ET
|
Y-mAbs Therapeutics, Inc
Completed resubmission to the FDA of omburtamab BLADANYELZA® adoption drove a 9% sequential revenue increase to $10.5 millionCompany issues 2022 full-year DANYELZA® revenue guidance of $45-$50...
Y-mAbs to Announce First Quarter 2022 Financial and Operating Results on May 9, 2022
May 03, 2022 16:01 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter March 31,...
Y-mAbs Announces Executive Management Changes and Provides 2022 Revenue Guidance and Financial Update
April 27, 2022 16:01 ET
|
Y-mAbs Therapeutics, Inc
CEO and Board Member Dr. Claus Moller has stepped down; Thomas Gad, Founder, Chairman and President assumes Interim CEO role and steps down as Chairman; Dr. Jim Healy to be appointed as...
Y-mAbs Announces Presentation of SADA Technology at AACR
April 08, 2022 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Announces Submission of Omburtamab Biologics License Application to FDA
April 01, 2022 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, April 01, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Developments
February 24, 2022 16:01 ET
|
Y-mAbs Therapeutics, Inc
Announced completion of pre-BLA meeting with the FDA for omburtamab BLA resubmission expected by the end of first quarter 2022 DANYELZA® adoption drives sequential revenue increase Completed IND...